US FDA approves GE HealthCare’s diagnostic drug for the treatment of heart disease
The US Food and Drug Administration has approved a GE HealthCare diagnostic drug for use in the detection of coronary heart disease. Flyrcado, a radioactive diagnostic drug for positron emission tomography (PET) and myocardial perfusion imaging (MPI), will go on sale in some US markets in early 2025, after which it will be expanded.
POPULAR POSTS
IEA warns ‘electricity era’ will come after fossil fuels peak
October 17, 2024
Easter Island fights global plastic waste vortex
October 17, 2024
Egypt opens more galleries at its antiquities museum
October 17, 2024
LIVE STREAM